دورية أكاديمية
أعرض في EDS

Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults.

التفاصيل البيبلوغرافية
العنوان: Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults.
المؤلفون: Saloner R; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA., VandeVrede L; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA., Asken BM; Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA., Paolillo EW; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA., Gontrum EQ; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA., Wolf A; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA., Lario-Lago A; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA., Milà-Alomà M; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA., Triana-Baltzer G; Neuroscience Biomarkers, Janssen Research & Development, LLC, San Diego, California, USA., Kolb HC; Neuroscience Biomarkers, Janssen Research & Development, LLC, San Diego, California, USA., Dubal DB; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA., Rabinovici GD; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA., Miller BL; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA., Boxer AL; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA., Casaletto KB; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA., Kramer JH; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.
المصدر: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Jan; Vol. 20 (1), pp. 376-387. Date of Electronic Publication: 2023 Aug 28.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : Hoboken, NJ : John Wiley & Sons, Ltd.
Original Publication: Orlando, FL : Elsevier, Inc.
مواضيع طبية MeSH: Alzheimer Disease*/metabolism , Cognitive Dysfunction*, Adult ; Humans ; Female ; Male ; tau Proteins/metabolism ; Brain/metabolism ; Positron-Emission Tomography ; Atrophy/metabolism ; Biomarkers ; Amyloid beta-Peptides/metabolism
مستخلص: Introduction: Accumulating evidence indicates disproportionate tau burden and tau-related clinical progression in females. However, sex differences in plasma phosphorylated tau (p-tau)217 prediction of subclinical cognitive and brain changes are unknown.
Methods: We measured baseline plasma p-tau217, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) in 163 participants (85 cognitively unimpaired [CU], 78 mild cognitive impairment [MCI]). In CU, linear mixed effects models examined sex differences in plasma biomarker prediction of longitudinal domain-specific cognitive decline and brain atrophy. Cognitive models were repeated in MCI.
Results: In CU females, baseline plasma p-tau217 predicted verbal memory and medial temporal lobe trajectories such that trajectories significantly declined once p-tau217 concentrations surpassed 0.053 pg/ml, a threshold that corresponded to early levels of cortical amyloid aggregation in secondary amyloid positron emission tomography analyses. CU males exhibited similar rates of cognitive decline and brain atrophy, but these trajectories were not dependent on plasma p-tau217. Plasma GFAP and NfL exhibited similar female-specific prediction of medial temporal lobe atrophy in CU. Plasma p-tau217 exhibited comparable prediction of cognitive decline across sex in MCI.
Discussion: Plasma p-tau217 may capture earlier Alzheimer's disease (AD)-related cognitive and brain atrophy hallmarks in females compared to males, possibly reflective of increased susceptibility to AD pathophysiology.
(© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
References: Alzheimers Dement (Amst). 2021 May 27;13(1):e12204. (PMID: 34095436)
Alzheimers Dement. 2011 May;7(3):270-9. (PMID: 21514249)
Nat Med. 2022 Sep;28(9):1797-1801. (PMID: 35953717)
Ann Neurol. 2020 Nov;88(5):921-932. (PMID: 32799367)
Brain. 2010 Feb;133(Pt 2):512-28. (PMID: 20080878)
JAMA Neurol. 2021 Oct 1;78(10):1249-1254. (PMID: 34424272)
Neurology. 2016 Nov 1;87(18):1916-1924. (PMID: 27708128)
Biol Sex Differ. 2020 Jun 19;11(1):33. (PMID: 32560743)
Brain. 2020 Dec 5;143(11):3234-3241. (PMID: 33068398)
J Appl Lab Med. 2020 Jan 1;5(1):158-169. (PMID: 31811073)
Mol Neurodegener. 2023 Mar 16;18(1):18. (PMID: 36927491)
Brain. 2023 Sep 1;146(9):3719-3734. (PMID: 36967222)
Nat Med. 2022 Jul;28(7):1398-1405. (PMID: 35618838)
Ann Neurol. 2022 Jul;92(1):11-22. (PMID: 35471588)
Neurology. 2021 Nov 23;97(21):e2065-e2078. (PMID: 34556565)
JAMA. 2020 Aug 25;324(8):772-781. (PMID: 32722745)
Neurobiol Aging. 2021 Nov;107:70-77. (PMID: 34399127)
Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4. (PMID: 25443857)
JAMA Neurol. 2023 Feb 1;80(2):188-199. (PMID: 36508198)
J Alzheimers Dis. 2020;76(4):1413-1422. (PMID: 32651319)
Brain Commun. 2023 Mar 06;5(2):fcad057. (PMID: 37013174)
Neurology. 2019 Nov 12;93(20):e1881-e1889. (PMID: 31597708)
Alzheimers Dement. 2024 Jan;20(1):376-387. (PMID: 37639492)
JAMA Neurol. 2023 Apr 1;80(4):360-369. (PMID: 36745413)
JAMA Neurol. 2021 Dec 1;78(12):1471-1483. (PMID: 34661615)
Sci Transl Med. 2020 Aug 26;12(558):. (PMID: 32848093)
J Int Neuropsychol Soc. 2022 Jul;28(6):588-599. (PMID: 34158138)
Lancet Neurol. 2021 Sep;20(9):739-752. (PMID: 34418401)
Alzheimers Res Ther. 2019 Mar 21;11(1):27. (PMID: 30902090)
Alzheimers Dement. 2021 Aug;17(8):1353-1364. (PMID: 33580742)
Sci Rep. 2018 May 10;8(1):7490. (PMID: 29748598)
Cogn Behav Neurol. 2003 Dec;16(4):211-8. (PMID: 14665820)
Neuroimage. 2006 Jul 1;31(3):968-80. (PMID: 16530430)
Alzheimer Dis Assoc Disord. 2021 Apr-Jun 01;35(2):164-168. (PMID: 32520734)
Neurology. 2022 Aug 9;99(6):e594-e604. (PMID: 35577574)
Brain. 2022 Oct 21;145(10):3536-3545. (PMID: 35869598)
Neurology. 2022 Nov 14;99(20):e2285-e2293. (PMID: 36041868)
Alzheimers Dement (N Y). 2015 Sep 1;1(2):103-110. (PMID: 26451386)
Alzheimers Dement. 2022 Dec;18(12):2669-2686. (PMID: 35908251)
JAMA Neurol. 2022 Mar 01;79(3):228-243. (PMID: 35099509)
JAMA Neurol. 2019 May 1;76(5):542-551. (PMID: 30715078)
Nat Med. 2022 Dec;28(12):2555-2562. (PMID: 36456833)
Memory. 2013;21(7):857-74. (PMID: 23383629)
Brain Commun. 2020;2(1):fcaa025. (PMID: 32337508)
Alzheimers Res Ther. 2019 Dec 26;11(1):109. (PMID: 31878968)
JAMA Netw Open. 2021 Feb 1;4(2):e210169. (PMID: 33630089)
Mol Psychiatry. 2022 Oct;27(10):4314-4322. (PMID: 35768637)
Neuroimage. 2005 Jul 1;26(3):839-51. (PMID: 15955494)
Brain Imaging Behav. 2017 Feb;11(1):205-213. (PMID: 26843008)
Neuropsychology. 2020 Nov;34(8):835-850. (PMID: 33030915)
Alzheimers Dement. 2022 Jun;18(6):1128-1140. (PMID: 34569696)
Alzheimers Dement (Amst). 2022 Apr 05;14(1):e12307. (PMID: 35415202)
Alzheimers Dement. 2023 Aug;19(8):3448-3457. (PMID: 36807763)
Alzheimers Res Ther. 2022 May 14;14(1):67. (PMID: 35568889)
JAMA Neurol. 2021 Feb 1;78(2):149-156. (PMID: 33165506)
Neurobiol Aging. 2021 Sep;105:86-98. (PMID: 34049062)
Alzheimers Dement (Amst). 2022 Jul 12;14(1):e12321. (PMID: 35845260)
معلومات مُعتمدة: U19 AG063911 United States AG NIA NIH HHS; P30 AG062422 United States AG NIA NIH HHS; RF1 AG068325 United States AG NIA NIH HHS; P01 AG019724 United States AG NIA NIH HHS; RF1 AG079176 United States AG NIA NIH HHS; R01 AG072475 United States AG NIA NIH HHS; R01 AG032289 United States AG NIA NIH HHS; U54 NS092089 United States NS NINDS NIH HHS; R01 AG045611 United States AG NIA NIH HHS; K23 AG073514 United States AG NIA NIH HHS; UF1 NS100608 United States NS NINDS NIH HHS; AARF-23-1145318 United States ALZ Alzheimer's Association; L30 AG069301 United States AG NIA NIH HHS; K24 AG045333 United States AG NIA NIH HHS; AARF-22-974065 United States ALZ Alzheimer's Association; R01 AG048234 United States AG NIA NIH HHS; R01 AG038791 United States AG NIA NIH HHS
فهرسة مساهمة: Keywords: Alzheimer's disease; amyloid positron emission tomography; cognition; cognitively unimpaired; glial fibrillary acidic protein; medial temporal lobe; neurofilament light; phosphorylated tau217; plasma biomarkers; sex differences; verbal memory
المشرفين على المادة: 0 (tau Proteins)
0 (Biomarkers)
0 (Amyloid beta-Peptides)
تواريخ الأحداث: Date Created: 20230828 Date Completed: 20240118 Latest Revision: 20240712
رمز التحديث: 20240713
مُعرف محوري في PubMed: PMC10843677
DOI: 10.1002/alz.13454
PMID: 37639492
قاعدة البيانات: MEDLINE
الوصف
تدمد:1552-5279
DOI:10.1002/alz.13454